ICAR 2016:口服负载HBsAg的纳米颗粒疫苗或能增强免疫应答

2018-07-11 编辑:略晓薛 来源:一诺医学 作者:enjoylife
口服抗原是首选的用药途径,因为它服用方便,提高患者的依从性。口服途径的应用在疫苗接种中显得更加重要,因为它诱导粘膜以及全身的体液免疫反应和细胞免疫反应。乙型肝炎是一种严重的传染病,在慢性感染中,如果不及时治疗,会导致肝细胞癌、肝硬化,甚至死亡。文献表明,每年约有400万例急性乙型肝炎病毒(HBV)患者。
 
虽然来自重组DNA的肠外疫苗能够诱导约95%的受者的保护,但这种疫苗接种技术仍然表现出低的免疫反应,低效率的吸收和病人不依从。因此,一个额外的和可供选择的途径,如口服,这是更符合病人的管理。
 
本研究旨在探讨负载纳米粒子的乙肝表面抗原对免疫应答的影响。该纳米颗粒有望通过增强吸收提高免疫反应,控制释放,防止其降解。粒径157±12 nm,Zeta电位+ 32 + 3.6 mV的纳米粒子的82%封装的高效开发。体外释放分析显示控制HBsAg从颗粒中的释放,而使用CD光谱测定其在酶中的稳定性。体内研究通过5-6 只BALB/c小鼠显示,与普通的抗原相比,负载HBsAg的纳米粒可增强免疫应答。
 
 
英文原文
 
Hepatitis B Virus Surface Antigen Loaded Pluronic Grafted Chitosan Nanoparticles to Enhance Immunogenic Response by Oral Route
 
Shweta Sharma
Pharmaceutics division, CDRI, India
 
Oral delivery of antigen is preferred route for administration because of its convenience in administration which leads to improved patient compliance.Application of oral route becomes more important in case of vaccine delivery as it induces both mucosal as well as systemic humoral and cellular immune response. Hepatitis B is a serious infectious disease which in chronic infection causes hepatocellular carcinoma, cirrhosis and even death if left untreated. Literature reveals that approx 4 million clinical cases of acute Hepatitis B virus (HBV) ensues every year. Although parenteral vaccines derived from recombinant DNA are able to induce protection in about 95% of recipients but still this vaccination techniques exhibit low immune response,inefficient site for uptake and patient non-compliance. Hence an additional and alternative route of administration such as oral which is more patient compliant should be employed. The present study aims to investigate the effect of HBsAg loaded in nanoparticles over immunogenic response. The loaded nanoparticles are expected to improve immunogenic response by enhancing the uptake, controlling the release and preventing its degradation.The nanoparticles with particle size 157+12 nm and zeta potential +32+3.6 mV were developed with 82% encapsulation efficient. In vitro release analysis revealed the controlled release of HBsAg from nanoparticles whereas confirmation stability in enzymes was determined using CD spectra. In vivo studies in 5-6 BALB/c mice revealed enhance immunogenic response through HBsAg loaded nanoparticles in comparison to plain antigen。
 




本网站所有注明“来源:一诺医学”的文字、图片及音视频资料,版权均归一诺医学所有,其他平台转载需得到授权且注明:“来源:一诺医学”。本站所有转载文章系出于传递更多信息之目的,且明确注明来源和/或作者,不希望被转载的媒体和/或个人请与我们联系(0571-86635366),我们将立即进行删除处理。所有文章仅代表作者观点,不代表本站立场。

相关文章